rs2854747 — IGFBP3

Intronic variant in IGFBP3 — the gene encoding the main carrier protein for IGF-1 in circulation — associated with lower circulating IGFBP-3 levels in carriers of the G allele

See your personal result for IGFBP3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IGFBP3 and the IGF-1 Circuit — Your Growth Factor Traffic Control

Most of the insulin-like growth factor-1 (IGF-1) circulating in your blood is not free — it is bound to IGFBP-3 (insulin-like growth factor binding protein 3), a carrier protein that acts as both a reservoir and a gatekeeper for IGF-1. IGFBP-3 sequesters 75–90% of circulating IGF-111 75–90% of circulating IGF-1
IGF-1: a peptide hormone produced mainly by the liver that promotes cell growth, tissue repair, and anabolism throughout life — essential in childhood for linear growth and in adults for muscle maintenance, bone density, and metabolic balance in a large ternary complex together with the acid-labile subunit (ALS), regulating how much free IGF-1 reaches tissues at any moment.

Rs2854747 is an intronic variant in the IGFBP3 gene on chromosome 7, in a region of strong linkage disequilibrium22 linkage disequilibrium
Linkage disequilibrium (LD): when alleles at nearby positions are inherited together more often than expected by chance, making one variant a reliable proxy for another with several other IGFBP3 variants — including the well-studied -202 A/C promoter polymorphism (rs2854744). The G allele at rs2854747 tracks consistently with lower circulating IGFBP-3 levels across diverse populations.

The Mechanism

The IGFBP3 gene is on the minus (reverse) strand of chromosome 7. Rs2854747 sits within an intron and does not change the amino acid sequence of the IGFBP-3 protein directly. Its effect on circulating IGFBP-3 levels likely reflects linkage with functional regulatory variants33 linkage with functional regulatory variants
This is a common pattern in genetics: an intronic "tag" SNP travels with a causal variant in the promoter or enhancer that directly controls gene expression, making the tag SNP a reliable proxy even though it is not itself functional in the IGFBP3 promoter or enhancer region. The most studied of these is the -202 A/C polymorphism (rs2854744), where the A allele drives significantly higher promoter activity in vitro — a finding that mirrors the serum-level gradient (AA > AC > CC) observed in population studies.

When IGFBP-3 levels are genetically lower, more IGF-1 can circulate in its free, bioactive form. Free IGF-1 binds to the IGF-1 receptor, activating the PI3K/Akt/mTOR and MAPK/ERK pathways — promoting cell proliferation, survival, and anabolism. This is beneficial for muscle repair and bone maintenance but may increase long-term mitogenic pressure on epithelial tissues. Beyond its role as an IGF-1 carrier, IGFBP-3 also has IGF-independent anti-tumor actions44 IGF-independent anti-tumor actions
IGFBP-3 can enter cell nuclei where it interacts with retinoid X receptor-alpha (RXRα), shifting the RXRα/Nur77 complex toward mitochondrial targeting and triggering apoptosis — independent of IGF-1 entirely, including direct induction of apoptosis through caspase activation and p53 upregulation.

The Evidence

A landmark multiethnic study55 landmark multiethnic study
Cheng I et al. Genetic determinants of circulating IGF-I, IGFBP-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab, 2007 in 837 Multiethnic Cohort participants identified rs2854747 as one of five highly correlated IGFBP3 SNPs with strongly significant associations with circulating IGFBP-3 levels (Bonferroni-adjusted P from 7.75 × 10⁻⁸ to 1.44 × 10⁻⁵). Critically, the association was consistent across African American, Native Hawaiian, Japanese American, Latino, and white participants — a pattern rarely seen for complex trait associations, suggesting this is a robust signal rather than a population-specific finding.

The functional biology of the IGFBP3 locus was established earlier by Biernacka and colleagues66 Biernacka and colleagues
Biernacka JM et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab, 2001, who demonstrated in vitro that the A allele at position -202 drives significantly higher IGFBP3 promoter activity than the C allele, explaining the dose-dependent increase in serum levels with A allele count. The same study found that the relationship between circulating retinol and IGFBP-3 levels was genotype-dependent — occurring only in A allele carriers.

Quantitatively, a meta-analysis of 16 studies77 meta-analysis of 16 studies
Dong XB et al. IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep, 2009 found that the AA genotype (high IGFBP-3) was associated with approximately 546 ng/mL higher IGFBP-3 levels compared to CC homozygotes (95% CI 412–680 ng/mL), a clinically significant difference given that normal adult ranges span roughly 2,000–6,000 ng/mL. In terms of cancer risk, the C allele (low-IGFBP3 haplotype) was associated with a 7% increased breast cancer risk (OR 1.07, 95% CI 1.01–1.13 dominant model) and a borderline 13–18% increased prostate cancer risk, while higher IGFBP-3 protein levels were associated with a 56% reduction in advanced prostate cancer risk.

A comprehensive Caucasian analysis88 comprehensive Caucasian analysis
Travis RC et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk. Hum Mol Genet, 2010 of 5,684 participants found that the Gly32Ala missense variant (rs2854746, in strong LD with rs2854747) independently added approximately 6.3% higher IGFBP-3 per minor allele even after adjustment for the -202 promoter polymorphism — confirming that the IGFBP3 locus harbors multiple functional variants that collectively shape protein output.

Practical Implications

For individuals carrying one or two copies of the G allele at rs2854747, the practical signal is modest: circulating IGFBP-3 levels tend to run lower than in AA homozygotes, which translates to somewhat higher free IGF-1 bioavailability. This is not a pathological state — the G allele is common globally (~42%) — but it does make measuring the IGF-1/IGFBP-3 axis worth considering if you have other risk factors for IGF-related conditions (obesity, a sedentary lifestyle, high protein intake driving IGF-1 up, or a family history of prostate or breast cancer).

Nutritional factors that influence the IGFBP-3 system include zinc — a randomized trial99 randomized trial
Ortega I et al. Positive effects of zinc supplementation on growth, GH, IGF1, and IGFBP3 in eutrophic children. Eur J Clin Nutr, 2013 confirmed that zinc supplementation significantly increased both IGF-1 and IGFBP-3 in children — and adequate protein intake and vitamin D status, which support the liver's production of IGF-binding proteins.

Interactions

Rs2854747 is in strong linkage disequilibrium with several other IGFBP3 variants: rs2854744 (the -202 A/C promoter polymorphism), rs2854746 (the Gly32Ala exon 1 missense variant), rs11977526, rs3110697, and rs2132570. These SNPs form a correlated haplotype block across the IGFBP3 gene that collectively determines the majority of inter-individual genetic variation in circulating IGFBP-3 levels. Users who carry risk alleles at multiple variants within this haplotype are likely to have the most pronounced reduction in IGFBP-3 protein output.

For individuals carrying both low-IGFBP3 IGFBP3 variants and high-activity IGF1 variants (such as rs2162679 or rs6214), the combined effect would elevate free IGF-1 bioactivity more substantially than either gene alone.

Genotype Interpretations

What each possible genotype means for this variant.

AA Optimal IGFBP-3 Output Normal

Normal IGFBP-3 production — full support for IGF-1 regulation

The AA genotype at rs2854747 represents the most favorable genetic profile for IGFBP-3 production at this locus, consistent with higher promoter activity at the nearby -202 site. In meta-analysis data, AA individuals show approximately 546 ng/mL higher IGFBP-3 than CC carriers — a meaningful buffer that keeps free IGF-1 in check and may confer modest protection against IGF-related cancer risk.

Even at optimal genotype, circulating IGFBP-3 and IGF-1 levels are strongly influenced by diet (protein intake, zinc, vitamin D), body composition, age, and growth hormone secretion. A blood test remains the most reliable way to assess your actual IGF-1 and IGFBP-3 status.

AG Mildly Reduced IGFBP-3 Intermediate

Moderately reduced IGFBP-3 output — one copy of the lower-level allele

The AG genotype represents an intermediate state on the IGFBP3 expression spectrum. In population studies, circulating IGFBP-3 levels follow a clear additive gradient: AA > AG > GG. For AG carriers, the reduction in IGFBP-3 is approximately half that of GG homozygotes relative to AA — roughly 200–270 ng/mL lower than AA.

Importantly, the per-allele effect of rs2854747 and its linked variants on cancer risk is modest (OR ~1.03–1.07 per G allele in meta-analyses), and no genome-wide significant cancer risk association has been confirmed for this variant individually. The practical value of this result lies in confirming you are on the lower end of genetic IGFBP-3 output, which may be worth factoring into your broader health picture.

GG Reduced IGFBP-3 Output Reduced

Genetically lower IGFBP-3 — both copies of the lower-level allele

The GG genotype at rs2854747 represents the lowest IGFBP-3 genetic profile at this locus. Meta-analytic data on the linked IGFBP3 haplotype show approximately 546 ng/mL lower circulating IGFBP-3 in CC homozygotes (the equivalent of GG at rs2854747) compared to AA homozygotes — a difference that can shift an individual from the middle to the lower quartile of the IGFBP-3 distribution.

IGFBP-3 has dual roles: it keeps IGF-1 bound and inactive in the ternary complex (moderating mitogenic drive), and it exerts direct anti-proliferative and pro-apoptotic actions in tissues independently of IGF-1. Genetically lower IGFBP-3 therefore affects both arms of this biology. However, the per-SNP cancer risk elevation is modest in meta-analyses (OR ~1.07–1.13 in dominant or homozygote comparisons), and no direct clinical intervention guideline exists for this genotype.

Nutritionally modifiable factors that support IGFBP-3 production include zinc (required for GH-stimulated hepatic IGFBP-3 synthesis), vitamin D (which upregulates IGFBP-3 expression), and adequate dietary protein. Avoiding conditions that suppress GH secretion (obesity, insulin resistance) also protects IGFBP-3 output.